HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-pos...
Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer ( Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA )
23 Jan 2020
Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast c...
Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras
Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )
23 Jan 2020
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negativ...
Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )
19 Dec 2019
The challenges of treating breast cancer in Brazil
Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
The challenges of treating breast cancer in Brazil ( Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil )
19 Dec 2019
The importance of central pathology pCR review in an international multicenter n...
Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany
The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )
19 Dec 2019
SABCS 2019 highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
19 Dec 2019
The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- ...
Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain
The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )
19 Dec 2019
Imaging for women who are high risk of breast cancer
Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA
Imaging for women who are high risk of breast cancer ( Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA )
19 Dec 2019
Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women ...
Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA
Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer ( Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA )
19 Dec 2019
KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant...
Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA
KEYNOTE-522: Neoadjuvant pembro   chemo vs placebo   chemo, followed by adjuvant pembro vs placebo for early TNBC ( Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA )
19 Dec 2019
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes...
Prof William Symmans - MD Anderson Cancer Center, Houston, Texas
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )
19 Dec 2019
Implementation of genetic testing in breast cancer patients
Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA
Implementation of genetic testing in breast cancer patients ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )
19 Dec 2019